A Phase 2 interventional study of Triptorelin Pamoate (Pamorelin® LA 11.25 mg) in Prostate Cancer, sponsored by Ipsen. Completed at 22 sites in Germany. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-08.
Sponsored by Ipsen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.
Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 17th largest by enrollment, is one of 2 that started in 2010, is one of 7 in phase 2, and was the 9th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Cancer Research Antwerp · Sites in Belgium
Ages 18+ · Men only
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+ · Men only
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Sites in Spain
Ages 18+
Marco Lorenzo Bonu · Sites in Italy
Ages 18–80 · Men only
By country, each count listing its studies:
triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 13 · Phase 4 6
First in 2002; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 120 across the 28 interventional studies. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
26 studies in Prostatic Neoplasms by Ipsen: none open now, none under way, none of them phase 3. Of 26 finished, 12 (46%) have results posted.
Among the 26 studies in Prostatic Neoplasms by Ipsen, this one is the 8th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2010, is one of 5 in phase 2, and was the 5th registered.
Ipsen’s Prostatic Neoplasms studies by the year they started, since 2006.
1 of the studies testing triptorelin in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05851547Ottawa Hospital Research InstituteDose Escalation For INtraprostatic LEsions | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies testing triptorelin in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ipsen’s 26 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the pharmacodynamic equivalence of triptorelin pamoate (Pamorelin® LA 11.25 mg), applied either IM or SC, in terms of the area under the curve [AUC1-85day] for serum testosterone in patients with advanced prostate cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Triptorelin Pamoate (Pamorelin® LA 11.25 mg)
Drug: Triptorelin Pamoate (Pamorelin® LA 11.25 mg)
Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85. Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85.
Area Under the Curve of Testosterone Serum Concentration Between D1 and D85 (AUC1-85d).
Area under the curve (AUC) calculated from serum testosterone concentration taken at intervals between the first administration (Day 1) of the study drug and Day 85 after dosing. From the curve describing serum testosterone concentration levels (ng/mL) over time, the AUC was calculated using numerical integration methods. This value was log-transformed to more closely meet the assumption of the statistical method.
Time frame: 1, 3, 5, 8, 15, 22, 29, 57, 85 days post-dose
Area Under the Curve of Testosterone Serum Concentration Between D1 and D169 (AUC1-169d)
Area under the curve calculated from serum testosterone concentration taken at intervals between the first administration (Day 1) of the study drug and Day 169 after dosing. From the curve describing serum testosterone concentration levels (ng/mL) over time, the AUC was calculated using numerical integration methods. This value was log-transformed to more closely meet the assumption of the statistical method.
Time frame: 1, 3, 5, 8, 15, 22, 29, 57, 85, 87, 113, 141 and 169 days post-dose
Area Under the Curve of Testosterone Serum Concentration Between D85 and D169 (AUC85-169d)
Area under the curve calculated from serum testosterone concentration taken at intervals between Day 85 and Day 169 after dosing. From the curve describing serum testosterone concentration levels (ng/mL) over time, the AUC was calculated using numerical integration methods. This value was log-transformed to more closely meet the assumption of the statistical method.
Time frame: 85, 87, 113, 141 and 169 days post-dose
Maximum Concentration of Serum Testosterone [Cmax] - Raw Data
Cmax was assessed as the maximum testosterone serum concentration between the first administration of the study drug and Day 169.
Time frame: 1, 3, 5, 8, 15, 22, 29, 57, 85, 87, 113, 141 and 169 days post-dose
Maximum Concentration of Serum Testosterone [Cmax] - Log-transformed Data
Cmax was assessed as the maximum testosterone serum concentration between the first administration of the study drug and Day 169.
Time frame: 1, 3, 5, 8, 15, 22, 29, 57, 85, 87, 113, 141 and 169 days post-dose
Time to Castration [Tcast] - Testosterone Level Less Than or Equal to 0.5 ng/mL
tcast is the number of days between day of first administration of the study drug and the day the testosterone level reaches the limit of castration defined as testosterone level less than or equal to 0.5 ng/mL for the first time. Analysis of tcast was based on the Kaplan-Meier estimator.
Time frame: 12 weeks
Time to Castration [Tcast] - Testosterone Level Less Than 0.5 ng/mL
tcast is the number of days between day of first administration of the study drug and the day the testosterone level reaches the limit of castration defined as testosterone level less than 0.5 ng/mL for the first time. Analysis of tcast was based on the Kaplan-Meier estimator.
Time frame: 12 weeks
Patients diagnosed with advanced prostate cancer (locally advanced or metastatic, histologically proven) recruited at 23 investigational sites in Germany.
| Milestone | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. |
|---|---|---|
| Started | 52 | 51 |
| Completed | 46 | 45 |
| Not completed | 6 | 6 |
| Withdrew: Lack of efficacy | 3 | 3 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Death | 1 | 0 |
Area under the curve (AUC) calculated from serum testosterone concentration taken at intervals between the first administration (Day 1) of the study drug and Day 85 after dosing. From the curve describing serum testosterone concentration levels (ng/mL) over time, the AUC was calculated using numerical integration methods. This value was log-transformed to more closely meet the assumption of the statistical method.
| log(ng*day/mL) | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. |
|---|---|---|
| Area Under the Curve of Testosterone Serum Concentration Between D1 and D85 (AUC1-85d). | 4.24 ± 0.40 | 4.23 ± 0.50 |
Area under the curve calculated from serum testosterone concentration taken at intervals between the first administration (Day 1) of the study drug and Day 169 after dosing. From the curve describing serum testosterone concentration levels (ng/mL) over time, the AUC was calculated using numerical integration methods. This value was log-transformed to more closely meet the assumption of the statistical method.
| log(ng*day/mL) | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. |
|---|---|---|
| Area Under the Curve of Testosterone Serum Concentration Between D1 and D169 (AUC1-169d) | 4.49 ± 0.42 | 4.52 ± 0.56 |
Area under the curve calculated from serum testosterone concentration taken at intervals between Day 85 and Day 169 after dosing. From the curve describing serum testosterone concentration levels (ng/mL) over time, the AUC was calculated using numerical integration methods. This value was log-transformed to more closely meet the assumption of the statistical method.
| log(ng*day/mL) | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. |
|---|---|---|
| Area Under the Curve of Testosterone Serum Concentration Between D85 and D169 (AUC85-169d) | 2.80 ± 0.45 | 2.88 ± 0.38 |
Cmax was assessed as the maximum testosterone serum concentration between the first administration of the study drug and Day 169.
| ng/mL | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. |
|---|---|---|
| Maximum Concentration of Serum Testosterone [Cmax] - Raw Data | 5.74 ± 2.33 | 5.50 ± 2.35 |
Cmax was assessed as the maximum testosterone serum concentration between the first administration of the study drug and Day 169.
| log(ng/mL) | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. |
|---|---|---|
| Maximum Concentration of Serum Testosterone [Cmax] - Log-transformed Data | 1.67 ± 0.42 | 1.62 ± 0.42 |
tcast is the number of days between day of first administration of the study drug and the day the testosterone level reaches the limit of castration defined as testosterone level less than or equal to 0.5 ng/mL for the first time. Analysis of tcast was based on the Kaplan-Meier estimator.
| days | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. |
|---|---|---|
| Time to Castration [Tcast] - Testosterone Level Less Than or Equal to 0.5 ng/mL | 22.0 (22.0 to 23.0) | 22.0 (22.0 to 23.0) |
tcast is the number of days between day of first administration of the study drug and the day the testosterone level reaches the limit of castration defined as testosterone level less than 0.5 ng/mL for the first time. Analysis of tcast was based on the Kaplan-Meier estimator.
| days | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. |
|---|---|---|
| Time to Castration [Tcast] - Testosterone Level Less Than 0.5 ng/mL | 22.0 (22.0 to 23.0) | 22.0 (22.0 to 23.0) |
Collected over Throughout the treatment period: 169 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | — | 11/52 (21.2%) | 32/52 (61.5%) |
| Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. | — | 7/51 (13.7%) | 25/51 (49%) |
| Event | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. |
|---|---|---|
| Bladder outlet obstructionRenal and urinary disorders | 0/52 | 1/51 |
| HypertensionVascular disorders | 0/52 | 1/51 |
| Inguinal hernia, obstructiveGastrointestinal disorders | 1/52 | 1/51 |
| PlasmacytomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/52 | 1/51 |
| PyuriaRenal and urinary disorders | 0/52 | 1/51 |
| Rectal abscessInfections and infestations | 0/52 | 1/51 |
| Renal failure acuteRenal and urinary disorders | 0/52 | 1/51 |
| Subdural haematomaInjury, poisoning and procedural complications | 0/52 | 1/51 |
| Transient ischaemic attackNervous system disorders | 0/52 | 1/51 |
| Urethral stenosisRenal and urinary disorders | 0/52 | 1/51 |
| Event | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. |
|---|---|---|
| Hot flushVascular disorders | 15/52 | 14/51 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 5/52 | 4/51 |
| FatigueGeneral disorders | 0/52 | 3/51 |
| Urinary tract infectionInfections and infestations | 3/52 | 3/51 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/52 | 1/51 |
| NocturiaRenal and urinary disorders | 3/52 | 0/51 |
| Sleep disorderPsychiatric disorders | 3/52 | 0/51 |
Analysed from intent-to-treat (ITT) population comprised of 103 patients (SC: 52 and IM: 51 patients).
| Age, Continuous(years) | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. | Total |
|---|---|---|---|
| Mean | 73.4 ± 6.7 | 73.3 ± 7.0 | 73.3 ± 6.8 |
| Age, Customized(participants) | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. | Total |
|---|---|---|---|
| 50 to < 60 years | 2 | 2 | 4 |
| 60 to < 70 years | 10 | 11 | 21 |
| 70 to < 80 years | 30 | 31 | 61 |
| 80 to < 90 years | 10 | 7 | 17 |
| Sex: Female, Male(Participants) | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 52 | 51 | 103 |
| Race (NIH/OMB)(Participants) | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 52 | 51 | 103 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Karnofsky index (%)(participants) | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. | Total |
|---|---|---|---|
| 100% | 21 | 27 | 48 |
| 90% | 18 | 12 | 30 |
| 80% | 13 | 12 | 25 |
| Prostate specific antigen (PSA) level(ng/mL) | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. | Total |
|---|---|---|---|
| Mean | 47.1 ± 174.9 | 97.2 ± 368.0 | 71.7 ± 286.0 |
| Testosterone serum level(ng/mL) | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. | Total |
|---|---|---|---|
| Mean | 3.23 ± 1.28 | 3.12 ± 1.36 | 3.18 ± 1.31 |
| Tumour-related pain(cm) | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. | Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. | Total |
|---|---|---|---|
| Mean | 0.25 ± 0.58 | 0.37 ± 0.99 | 0.31 ± 0.81 |
The record gives a start of Dec 2010, a primary completion of Feb 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triptorelin